AKT1 and neoplasm: The VEGFR kinase inhibitor, Ki8751, and a phosphatidylinositol 3-kinase–Akt inhibitor, LY294002, effectively block tumor-induced MDR1 up-regulation, suggesting that VEGF in the tumor microenvironment is an underlying factor in acquired drug resistance [19].